Abstract:BACKGROUND: Patients with adult-onset growth hormone deficiency have reduced bone density and increased fat mass. Growth hormone at high doses may decrease body fat in these patients, but the effects of growth hormone at more physiologic doses on bone density and body composition have not been convincingly shown.OBJECTIVE: To determine whether long-term growth hormone therapy at a dose adjusted to maintain normal insulin-like growth factor 1 (IGF-1) levels has clinical effects in patients with adult-onset growth hormone deficiency.DESIGN: Randomized, placebo-controlled study.SETTING: Tertiary referral center.PATIENTS: 32 men with adult-onset growth hormone deficiency.INTERVENTION: Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months. The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.MEASUREMENTS: Body composition and bone mineral density of the lumbar spine, femoral neck, and proximal radius were measured by dual energy x-ray absorptiometry at 6-month intervals. Markers of bone turnover were also measured during the first 12 months of the study.RESULTS: Growth hormone therapy increased bone mineral density in the lumbar spine by a mean (+/- SD) of 5.1% +/- 4.1% and bone mineral density in the femoral neck by 2.4% +/- 3.5%. In the growth hormone group, significant increases were seen in the following markers of bone turnover: osteocalcin (4.4 +/- 3.6 mg/L to 7.2 +/- 4.6 mg/L) and urinary pyridinoline (39.0 +/- 19.8 nmol/mmol of creatinine to 55.7 +/- 25.5 nmol/mmol of creatinine) and deoxypyridinoline (8.4 +/- 7.1 nmol/mmol of creatinine to 14.9 +/- 9.4 nmol/mmol of creatinine). Percentage of body fat in the growth hormone group decreased (from 31.9% +/- 6.5% to 28.3% +/- 7.0%), and lean body mass increased (from 59.0 +/- 8.5 kg to 61.5 +/- 6.9 kg). These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).CONCLUSIONS: Growth hormone administered to men with adult-onset growth hormone deficiency at a dose adjusted according to serum IGF-1 levels increases bone density and stimulates bone turnover, decreases body fat and increases lean mass, and is associated with a low incidence of side effects.

Growth hormone and bone: a basic perspective

[Effects of Recombinant Human Growth Hormone (GH) Replacement Therapy on Bone Metabolism in Children with GH Deficiency].

Effects of growth hormone and its secretagogues on bone

Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis

Ghrelineffects on the growth hormone release, osteoblast proliferation and bone growth

Impact of Growth Hormone Replacement on Bone Mass and Body Composition

Growth and Growth Hormone through the Ages: Art and Science

Growth hormone-releasing hormone and its analogues in health and disease

Effects of Physiologic Growth Hormone Therapy on Bone Density and Body Composition in Patients with Adult-Onset Growth Hormone Deficiency

Role of bisphosphonates in osteoporosis caused by adult growth hormone deficiency

Effects of Growth Hormone on Osteoarthritis Development

Two years in growth hormone 2017-18

Gut hormones and bone homeostasis: potential therapeutic implications

Renal effects of growth hormone in health and in kidney disease

Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy

Growth Hormone and Aging: Updated Review

The effects and correlations of recombinant human growth hormone replacement therapy on the bone metabolism in children with growth hormone deficiency

Clinical, Diagnostic, and Therapeutic Aspects of Growth Hormone Deficiency During the Transition Period: Review of the Literature

Growth hormone replacement may influence the biological action of thyroid hormone on liver and bone tissue

Growth Hormone and Cancer: an Update on Progress

Growth Hormone (GH) and Cardiovascular System